Show simple item record

dc.contributor.authorCherrez Ojeda, Iván
dc.contributor.authorMaurer, Marcus
dc.contributor.authorBernstein, Jonathan A
dc.contributor.authorVanegas, Emanuel
dc.contributor.authorFélix, Miguel
dc.contributor.authorRamón, Germán D.
dc.contributor.authorEnsina, Luis Felipe
dc.contributor.authorLarco Sousa, José Ignacio
dc.contributor.authorMatos Benavides, Edgar Emilio
dc.contributor.authorCardona Villa, R.
dc.contributor.authorLatour Staffeld, P.
dc.contributor.authorMorfin-Maciel, Blanca María
dc.contributor.authorMori, José
dc.contributor.authorWilches C, Paul
dc.contributor.authorMata, Valeria L.
dc.contributor.authorCherrez, Annia
dc.identifier.citationCherrez Ojeda I, Maurer M, Bernstein JA, Vanegas E, Félix M, Ramon GD, et al. Learnings from real-life experience of using omalizumab for chronicurticaria in Latin America. World Allergy Org. J. 2019 ; 12(2) : 12es_ES
dc.description.abstractUpdated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (CU), while other drugs, such as omalizumab, are conceived as second-line alternatives. In regards to omalizumab, despite advances in the management of CU, there are still open questions about timing, dosing, and objective measures for clinical response. This study was designed to portray the use of patient-reported outcomes (PROs) in chronic urticaria management, as well as the effectiveness and treatment patterns of omalizumab in CU, as seen in a real-life setting in Latin America. Methods: This is a retrospective observational study, involving 72 Latin American patients with chronic urticaria treated with omalizumab. Patient reported outcomes and treatment patterns, response, quality of life improvement and discontinuation were analyzed. Results: From the 72 patients, 91.7% (n ¼ 66) were assessed through PROs, where urticaria control test (UCT) was the most used (79.2%; n ¼ 57). Overall, 80.0% (n ¼ 44) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most patients assessed with CU-Q2oL improved quality of life (80.8%; n ¼ 21). With respect to omalizumab discontinuation, 20.8% (n ¼ 15) patients interrupted omalizumab before the 3rd month of treatment (p ¼ .000).es_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.subjectChronic spontaneous urticaria, Patient-reported outcomes, Omalizumab, Quality of life, Latin Americaes_ES
dc.subjectCalidad de vidaes_ES
dc.subjectMedición de Resultados Informados por el Pacientees_ES
dc.subjectAmérica Latinaes_ES
dc.titleLearnings from real-life experience of using omalizumab for chronicurticaria in Latin Americaes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional